Amorphous Solid Dispersion HCV Drug Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection, such as those using peginterferon-alpha and ribavirin, are limited by substantial side effects and incomplete viral elimination, necessitating the development of new drugs for effective HCV treatment.
Innovation Solution
The development of solid pharmaceutical compositions comprising potent HCV protease inhibitors (Compound 1) and NS5A inhibitors (Compound 2) in amorphous solid dispersions, formulated with pharmaceutically acceptable hydrophilic polymers and surfactants, which are combined in various forms like tablets or mini-tablets to enhance bioavailability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If new HCV drugs (protease inhibitors and NS5A inhibitors) are developed to improve treatment efficacy, then viral elimination and bioavailability are enhanced, but formulation complexity and manufacturing difficulty increase
Solution Approach 1:
The patent employs amorphous solid dispersion technology to create composite formulations combining protease inhibitors and NS5A inhibitors with hydrophilic polymers and surfactants. This composite approach enhances drug solubility and bioavailability while maintaining treatment efficacy, resolving the contradiction between improved therapeutic effect and formulation complexity.
Solution Approach 2:
The patent utilizes parameter changes by transitioning drugs from crystalline to amorphous state, altering physical and chemical properties to improve solubility and bioavailability. This parameter transformation enables effective delivery of potent HCV inhibitors while managing formulation challenges through controlled amorphization processes.
2Quantity of substance
If amorphous solid dispersions are used to enhance drug solubility and bioavailability, then treatment efficacy improves, but formulation stability and manufacturing precision become more challenging
Solution Approach 1:
The patent introduces hydrophilic polymers and surfactants as intermediary substances that facilitate the formation of stable amorphous solid dispersions. These mediators prevent drug crystallization, enhance solubility, and improve bioavailability while providing a robust platform for consistent manufacturing, thereby addressing both bioavailability enhancement and manufacturing precision requirements.
Solution Approach 2:
The patent applies parameter changes by controlling the physical state of drugs in amorphous form and adjusting formulation parameters such as polymer concentration, surfactant type, and processing conditions. These parameter optimizations enable precise control over drug release profiles and formulation stability, achieving high bioavailability with manufacturable precision.
3Reliability
If multiple HCV inhibitors are combined in single formulations, then treatment efficacy and viral elimination improve, but side effects and formulation complexity increase
Solution Approach 1:
The patent merges protease inhibitors and NS5A inhibitors into single combined formulations with optimized dosing ratios. This merging strategy achieves synergistic antiviral effects that improve viral elimination while reducing the need for multiple separate medications, thereby potentially reducing overall side effect burden and simplifying treatment regimens despite increased formulation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions provide improved bioavailability and efficacy in treating HCV infection, with enhanced release profiles and reduced side effects, effectively addressing the limitations of existing treatments.
Implementation Method 1
solid pharmaceutical compositions comprising potent HCV protease inhibitors (Compound 1) and NS5A inhibitors (Compound 2) in amorphous solid dispersions
Data Source
AI summary
The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.